Allspring Global Investments’s Cue Biopharma CUE Stock Holding History

Allspring Global Investments’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-90	Closed	-$13K	–	2742
2022 Q1	$13K	Buy	+90	New	+$19.1K	﹤0.01%	2962

Other funds holding CUE

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Allspring Global Investments's CUE Position: Q2 2022 in Review

Allspring Global Investments sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 90 shares — an estimated $13K sold.

Allspring Global Investments first reported a position in CUE in Q1 2022 and held it in 1 quarter. The position peaked at $13K in Q1 2022. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

Allspring Global Investments reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
Allspring Global Investments sold 90 Cue Biopharma shares in Q2 2022, an estimated $13K.
Allspring Global Investments first reported a position in Cue Biopharma in Q1 2022 and held it in 1 quarter.
Allspring Global Investments's Cue Biopharma position peaked at $13K in Q1 2022.
75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.